Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how to increase uptake.

Fintel reports that on March 13, 2025, Citigroup initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) ...

Vaccine hesitancy and higher rates of school vaccine exemptions increases the risk of outbreaks of preventable diseases, creating a significant health risk for vulnerable populations.

Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...

The mRNA technology behind coronavirus vaccines is now being used to create bespoke vaccines for cancer patients.

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

TD Cowen lowered the firm’s price target on BioNTech (BNTX) to $110 from $122 and keeps a Hold rating on the shares. The firm updated its model ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...